BCDA CEO Peter Altman Buys Additional Shares
CEO Peter Altman acquired 1,500 BCDA shares at $0.85 each.
Key Points
- Peter Altman, President and CEO of BCDA, purchased 1,500 shares on June 17, 2026, at an average price of $0.85.
- BCDA shares traded near $0.97 on Monday, with several institutional investors adjusting their holdings.
- HC Wainwright & Co. reiterated its 'buy' rating for BCDA, maintaining a price target of $25.00.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Peter Altman, the President and CEO of BCDA, has increased his stake in the company by purchasing 1,500 shares on June 17, 2026. He acquired these shares at an average price of $0.85 each, totaling approximately $1,275. This transaction was not part of a pre-planned trading program.
Insider Buying and Selling at BioCardia, Inc.
Peter Altman has been actively buying BCDA shares recently. On June 18, 2026, he bought 800 shares at $0.96 each. Earlier in the month, on June 9, he purchased 5,000 shares at $0.85. His purchases continued back into May, with acquisitions on May 20 and May 19 at prices of $0.92 and $0.95, respectively.
Other Institutional Activity in BCDA
Several institutional investors have also been adjusting their positions in BCDA. CM Management, LLC held steady with 130,000 shares valued at $157,300. Vanguard Capital Management LLC opened a new position with 124,591 shares worth about $150,755. Geode Capital Management, LLC increased its stake by 28,284 shares, bringing its total to 94,287 shares valued at $114,086. Meanwhile, Citadel Advisors LLC reduced its holdings by 30,863 shares to 63,384 shares, valued at $76,695.
BioCardia, Inc. Stock Down 17.8%
BCDA shares traded near $0.97 on Monday. The company's stock has been volatile, with institutional investors and insiders actively trading. While specific financial ratios and metrics are unavailable, the stock's recent activity suggests a dynamic investment environment.
$BCDA stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 9, 2026, HC Wainwright & Co. reiterated its 'buy' rating for BCDA, maintaining a price target of $25.00. This firm has consistently supported the stock, reflecting confidence in its potential.
About BCDA
BCDA is involved in the biotechnology sector, focusing on developing innovative medical solutions. The company is led by President and CEO Peter Altman, who has been actively increasing his personal investment in the firm. BCDA's headquarters are located in the United States, and it continues to engage in research and development to advance its offerings.
Bottom Line
Peter Altman's recent share purchases demonstrate his commitment to BCDA. Investors often track insider buying for insights into company leadership's confidence. While institutional activity provides a broader view of market sentiment, the latest transactions highlight a mix of new investments and adjustments. As always, remember that 13F filings and insider reports are backward-looking and may not represent current positions.
Get BioCardia, Inc. alerts
New 13F filings, insider trades, and analyst moves on $BCDA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.